166398-41-0

Basic information

• Product Name: N-Methyl-1,4-dioxaspiro[4.5]decan-8-aMine
• Synonyms: N-Methyl-1,4-dioxaspiro[4.5]decan-8-aMine
• CAS NO: 166398-41-0
• Molecular Formula: C₉H₁₇NO₂
• Molecular Weight: 171.23678
• Mol File: 166398-41-0.mol

Chemical Properties

• Boiling Point: 256.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.06±0.1 g/cm3(Predicted)
• PKA: 10?+-.0.20(Predicted)
• CAS DataBase Reference: N-Methyl-1,4-dioxaspiro[4.5]decan-8-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methyl-1,4-dioxaspiro[4.5]decan-8-aMine(166398-41-0)
• EPA Substance Registry System: N-Methyl-1,4-dioxaspiro[4.5]decan-8-aMine(166398-41-0)

Safety Data

• Hazardous Substances Data: 166398-41-0(Hazardous Substances Data)

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 74-89-5 methylamine 
• 730961-09-8 4-[(benzylamino)methyl]cyclohexanone ethylene acetal 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 1297611-94-9 4-(1H-Indol-3-yl)-N-methylcyclohex-3-enamine 
• 1312333-18-8 C₂₆H₄₁N₃ 
• 2976-84-3 4-methylaminocyclohekxanone 
• 1365155-89-0 6-(4-(Benzyl(methyl)amino)cyclohexyl)-N,N-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-amine 
• 1365154-12-6 4-(3,4-Dihydro-2,6-naphthyridin-2(1H)-yl)-N-methylcyclohexanamine 
• 1365156-20-2 N-Benzyl-4-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-N-methylcyclohexanamine 
• 1365155-94-7 tert-Butyl 4-(2-(dimethylamino)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)cyclohexyl(methyl)carbamate 
• 1365563-52-5 (3R)-3-[(2-chlorobenzoyl)amino]-N-methyl-N-[4-(1,2,3,4-tetrahydro-[2,6]-naphthyridin-2-yl)cyclohexyl]-2,3-dihydro-1H-indene-5-carboxylic acid amide 
• 1365154-07-9 N,N-dimethyl-6-(4-(methylamino)cyclohexyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-amine 
• 1414848-11-5 tert-butyl N-methyl-[9-(3-(trifluoromethyl)phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]carbamate 
• 1414848-12-6 tert-butyl N-methyl-[6-methoxy-9-(3-trifluoromethyl phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl] carbamate 
• 1414848-00-2 N-methyl-[9-(3-trifluoromethylphenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amine 
• 22350-03-4 N-methyl-(2,3,4,9-tetrahydro-1H-carbazol-3-yl)amine 
• 1187081-22-6 N-(1,4-dioxa-spiro[4.5]dec-8-yl)-4-fluoro-N-methyl-benzenesulfonamide 

Relevant articles and documents

A palladium/norbornene cooperative catalysis to access N-containing bridged scaffolds

A palladium/norbornene cooperative catalysis promoted annulation involving an ortho-C-H amination and intramolecular Heck cascade between aryl iodides and functionalized amination reagents is reported, thereby providing a highly convergent access to the u

CRYSTALLINE FORMS

The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)- 2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystal

AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS

The present invention relates to azaindole acetic acid derivatives of formula (I), (I) wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS

The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2

N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists

The design, synthesis and SAR of novel tetrahydrocarbazole derivatives having 5-HT6 receptor antagonist activity is presented. The racemic compound 15e was found to possess desirable pharmacokinetic properties, adequate brain penetration and activity in animal models of cognition.

Substituted Benzamide Compounds

Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

Biotin tethered homotryptamine derivatives: High affinity probes of the human serotonin transporter (hSERT)

Quantum dot conjugates of compounds capable of inhibiting the serotonin transporter (SERT) could form the basis of fluorescent probes for live cell imaging of membrane bound SERT. Additionally, quantum dot-SERT antagonist conjugates may be amenable to flu

CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in c

MEDICAMENTS

A compound of formula (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.

Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors

The disclosure relates to compounds of formula (I): wherein R1-R5, A and Y are as defined in the disclosure, to compositions comprising said compounds, and to processes for making and methods of using the same.